Clinical Scorecard: Novartis and BMS Pause Autoimmune CAR T Trials Over Safety Concerns
At a Glance
| Category | Detail |
|---|---|
| Condition | Autoimmune diseases |
| Key Mechanisms | CD19-directed CAR T therapies |
| Target Population | Patients with autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and others |
| Care Setting | Clinical trials |
Key Highlights
- Novartis paused eight studies of rapcabtagene autoleucel after three patients developed IEC-HS.
- All three patients with IEC-HS complications died.
- Bristol Myers Squibb paused enrollment in trials of zolacabtagene autoleucel due to safety monitoring findings.
- IEC-HS is a known risk associated with CAR T treatments.
- Patients already treated will continue to be monitored.
Guideline-Based Recommendations
Diagnosis
- Monitor for signs of IEC-HS in patients receiving CAR T therapies.
Management
- Pause trials and review safety data when serious adverse events occur.
Monitoring & Follow-up
- Implement routine safety monitoring during clinical trials.
Risks
- Be aware of the potential for life-threatening reactions such as IEC-HS.
Patient & Prescribing Data
Patients with autoimmune diseases participating in clinical trials.
Both therapies are autologous CAR T treatments with known risks.
Clinical Best Practices
- Engage independent safety boards for review of adverse events.
- Ensure ongoing monitoring of patients already treated in paused trials.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
